LONDON (Alliance News) - GlaxoSmithKline PLC on Wednesday said its Trelegy Ellipta treatment showed results better than two other treatments in tests over its efficacy for chronic obstructive pulmonary disease.
In the study, which Glaxo carried out alongside Innoviva Inc, Trelegy Ellipta posted superior results to two different classes of dual combination therapy, Relvar/Breo and Anoro, on the primary endpoint of reduction in the annual rate of on-treatment moderate of severe exacerbations.
It also showed better results on other outcomes such as lung function and quality of life.
Off-treatment data will also need to be considered, Glaxo said, and work is ongoing.
Head of Respiratory Therapy Area Research & Development Dave Allen said: "Reducing exacerbations to keep patients out of hospital is a key goal of COPD management alongside improving lung function and quality of life.
"The IMPACT study shows how Trelegy Ellipta can help patients with a history of exacerbation achieve these goals. We believe its publication in NEJM is an important addition to the evidence base that informs the management of this progressive and debilitating disease."
Glaxo shares were up 0.7% on Wednesday at a price of 1,421.80 pence each.